1.2 Type 2 Diabetes Mellitus Management

Type 2 Diabetes Mellitus Management

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. Modern clinical practice has transitioned from a glucocentric approach to a patient-centered framework that prioritizes organ protection, cardiovascular risk reduction, and weight management alongside glycemic control.

1. Diagnostic Criteria and HbA1c Targets

Diagnosis of Diabetes

A diagnosis of diabetes mellitus is established based on any of the following criteria, which must be confirmed on repeat testing on a separate day in the absence of unequivocal symptoms of hyperglycemia:

1. Fasting Plasma Glucose (FPG): >= 126 mg/dL (7.0 mmol/L) after an 8-hour fast.
2. 2-Hour Postprandial Glucose: >= 200 mg/dL (11.1 mmol/L) during a standardized 75-g Oral Glucose Tolerance Test (OGTT).
3. Glycated Hemoglobin (HbA1c): >= 6.5%.
4. Random Plasma Glucose: >= 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or a hyperglycemic crisis.

Glycemic Targets

Glycated hemoglobin (HbA1c) targets must be individualized based on patient characteristics:

• General Target (< 7.0%): Appropriate for most non-pregnant adults to minimize microvascular (nephropathy, retinopathy, neuropathy) and macrovascular complications.
• Stringent Target (< 6.5%): Appropriate for younger, newly diagnosed patients with a long life expectancy, minimal cardiovascular disease, and low risk of severe hypoglycemia.
• Less Stringent Target (< 8.0% to 8.5%): Appropriate for older adults, patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, or extensive comorbidities.

---

2. First-Line Pharmacotherapy: Metformin

Metformin (a biguanide) remains the foundational first-line pharmacological therapy for T2DM, unless contraindicated.

• Mechanism of Action: Primarily decreases hepatic gluconeogenesis by activating AMP-activated protein kinase (AMPK). It also increases peripheral insulin sensitivity in skeletal muscle and reduces intestinal glucose absorption.
• Clinical Profile: Metformin is weight-neutral or associated with modest weight loss, does not cause hypoglycemia when used as monotherapy, and is highly cost-effective.
• Adverse Effects:
  • Gastrointestinal (GI): Diarrhea, abdominal cramping, nausea, and metallic taste are common. These can be minimized by gradual dose titration and taking the medication with meals, or switching to an extended-release formulation.
  • Vitamin B12 Deficiency: Long-term use is associated with impaired B12 absorption; periodic monitoring is recommended.
  • Lactic Acidosis: A rare but highly lethal adverse effect.
• Contraindications: Absolute contraindication in patients with severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m². Metformin should not be initiated if the eGFR is between 30–45 mL/min/1.73m²; if a patient's eGFR drops to this range while on therapy, the dose should be reduced by 50% with close renal monitoring.

---

3. Cardiorenal Protective Classes: SGLT2i and GLP-1 RA

For patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), clinical guidelines (ADA/EASD) mandate the addition of an SGLT2 inhibitor or a GLP-1 receptor agonist with proven cardiovascular benefit. This recommendation is independent of the patient's baseline HbA1c or metformin use.

A. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i)

• Agents: Empagliflozin, Dapagliflozin, Canagliflozin.
• Mechanism of Action: Block the SGLT2 cotransporters in the proximal convoluted tubule of the nephron, preventing renal glucose and sodium reabsorption. This promotes urinary glucose excretion (glucosuria) and osmotic diuresis.
• Indications: Strongly preferred in patients with heart failure (both HFrEF and HFpEF, as they reduce HF hospitalizations) and CKD progression (reducing albuminuria and decline in eGFR).
• Adverse Effects:
  • Genitourinary mycotic infections (vulvovaginal candidiasis, balanitis) due to high urinary glucose.
  • Urinary tract infections (UTIs) and volume depletion/hypotension.
  • Euglycemic Diabetic Ketoacidosis (eDKA): DKA presenting with normal or only mildly elevated blood glucose levels (< 250 mg/dL). SGLT2 inhibitors must be held 3–4 days before scheduled major surgeries to avoid this complication.

B. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA)

• Agents: Semaglutide, Liraglutide, Dulaglutide.
• Mechanism of Action: Mimic endogenous incretin hormones. They stimulate glucose-dependent insulin secretion, suppress postprandial glucagon release, slow gastric emptying (delaying carbohydrate absorption), and promote central satiety.
• Indications: Preferred in patients with established ASCVD (reducing major adverse cardiovascular events like stroke and myocardial infarction) and in patients where weight loss is a primary clinical goal.
• Adverse Effects: Dose-dependent nausea, vomiting, and diarrhea. There is a small risk of acute pancreatitis.
• Contraindications: Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Menplasia type 2 (MEN 2), due to risk of thyroid C-cell tumors observed in animal models.

---

4. Insulin Step-Up Therapy

Insulin therapy is required when beta-cell function declines to a point where non-insulin agents cannot maintain glycemic control, or during periods of acute metabolic decompensation.

Indications for Early Insulin Initiation

Insulin should be initiated immediately in patients with:

• Severe hyperglycemia: blood glucose >= 300 mg/dL (16.7 mmol/L).
• Significantly elevated HbA1c: >= 10.0%.
• Clinical signs of catabolism: unexplained weight loss, ketonuria, or severe symptomatic polyuria/polydipsia.

Step-Up Protocol

1. Basal Insulin: Initiate long-acting insulin (e.g., Glargine, Detemir, Degludec) at 10 units daily or 0.1–0.2 units/kg/day.
2. Titration: Adjust the dose by 2 units every 3 days to achieve a target fasting blood glucose of 80–130 mg/dL without hypoglycemia.
3. Prandial Insulin: If fasting glucose is at target but the HbA1c remains elevated (or if postprandial glucose peaks exceed 180 mg/dL), initiate rapid-acting insulin (e.g., Aspart, Lispro) before the largest meal (known as a basal-plus regimen) at 4 units or 10% of the basal dose. Titrate up to a full basal-bolus regimen (rapid-acting insulin before each meal) as required.